Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

A matching-adjusted indirect comparison (MAIC) of zanubrutinib vs venetoclax + ibrutinib in treatment-naive chronic lymphocytic leukemia (CLL)

View Full Paper
Ask AI
Bookmark
Share

Authors

TMTalha MunirLMLeyla Mohseninejad

Discussion

Loading...

Member takes

Overview

Population-adjusted indirect comparison finds treatment benefit for zanubrutinib over V+I in CLL, implying improved outcomes yet limited power due to heterogeneity.

Key Points

  • To compare the effectiveness of zanubrutinib versus venetoclax combined with ibrutinib in treatment-naive CLL patients.
  • Conducted a population-adjusted indirect comparison using MAIC.
  • Matched individual patient data from trial arms of SEQUOIA to those of GLOW and CAPTIVATE.
  • Evaluated progression-free survival (PFS) outcomes using Cox regression for hazard ratios.
  • Zanubrutinib showed a significant PFS benefit over venetoclax plus ibrutinib in the GLOW patient population.
  • In SEQUOIA vs CAPTIVATE, zanubrutinib showed a favorable trend but lacked statistical significance due to reduced sample size.
  • The adjusted hazard ratio for PFS favored zanubrutinib with an HR of 0.54 in the CAPTIVATE comparison.

Cite This Study

Munir et al. (2025) studied this question.

synapsesocial.com/papers/69362f484fa91c937236d6b3https://doi.org/10.1182/blood-2025-7436
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Indirect Comparisons of the Efficacy and Safety of Zanubrutinib versus Venetoclax plus Obinutuzumab in Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma2025
  2. 2Indirect Comparison of the Efficacy of Zanubrutinib vs Ibrutinib and Acalabrutinib in Treatment-Naive Chronic Lymphocytic Leukemia: 6-Year Follow-Up2026
  3. 3Indirect comparison of efficacy of zanubrutinib vs ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma2025 · 1 citations
  4. 4Comparative efficacy of Bruton tyrosine kinase inhibitors in the treatment of relapsed/refractory chronic lymphocytic leukemia: A network meta-analysis (NMA).2024 · 3 citations
  5. 5Real-world safety and effectiveness of zanubrutinib vs ibrutinib in CLL: the CLL-ZANU2024 Italian cohort2026 · 4 citations